PHG vs ZBH: Koninklijke Philips NV ADR and Zimmer Biomet compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Koninklijke Philips NV ADR is the larger company, worth $23.5B, about 1.3 times Zimmer Biomet.
- Zimmer Biomet grew revenue faster over the last year (+4.8% vs -1.0%).
- Zimmer Biomet keeps more of each dollar of revenue as operating profit (14.2% vs 8.0%).
- On earnings, Koninklijke Philips NV ADR is the cheaper stock (21.2x vs 24.0x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | PHG | ZBH |
|---|---|---|
| Market cap | $23.5B | $17.9B |
| Share price | $24.24 | $89.14 |
| Revenue (last fiscal year) | $17.8B | $8.2B |
| Free cash flow (last fiscal year) | — | $1.5B |
| Revenue growth, last year | -1.0% | +4.8% |
| Revenue growth per year, last 5 fiscal years | +1.0% | +4.8% |
| Operating margin | 8.0% | 14.2% |
| Net margin | 5.0% | 9.5% |
| Return on equity | 8.2% | 6.4% |
| P/E (trailing) | 21.2x | 24.0x |
| Price / free cash flow | 26.3x | 12.2x |
| EV / EBITDA | 9.83x | 12.2x |
| FCF growth the price implies | — | -1.5% |
| Dividend yield | 4.1% | 1.0% |
| Debt / equity | 1.46x | 0.81x |
| Fundamental grade | D | B |
| Superinvestors holding it | 3 | 8 |
| Insider purchases, last 12 months | 0 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Koninklijke Philips NV ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $17.2B | — | 3.2% |
| 2022 | $17.8B | — | -8.6% |
| 2023 | $18.2B | — | -0.63% |
| 2024 | $18.0B | — | 2.9% |
| 2025 | $17.8B | — | 8.0% |
Zimmer Biomet
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $6.8B | $1.4B | 12.6% |
| 2022 | $6.9B | $1.2B | 10.0% |
| 2023 | $7.4B | $1.3B | 17.3% |
| 2024 | $7.7B | $1.3B | 16.7% |
| 2025 | $8.2B | $1.5B | 13.3% |
Where the revenue comes from
Koninklijke Philips NV ADR · by segments, 2025
Diagnosis & Treatment$8.5B48%
Connected Care$5.1B28%
Personal Health$3.7B21%
Other$554M3%
Zimmer Biomet · by products, 2025
Knees$3.3B40%
S.E.T$2.2B26%
Hips$2.1B25%
Technology & Data, Bone Cement and Surgical$666M8%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open PHG in InvestinglyQuestions
Which is bigger, Koninklijke Philips NV ADR or Zimmer Biomet?
Koninklijke Philips NV ADR (PHG), at $23.5B against $17.9B.
Is PHG or ZBH cheaper?
By trailing P/E, Koninklijke Philips NV ADR (21.2x) is cheaper than Zimmer Biomet (24.0x). A lower multiple can also mean the market expects less growth.
Which grows faster, PHG or ZBH?
Zimmer Biomet: revenue grew +4.8% over the last year, against -1.0%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.